Vaccine Scheduler
Meningococcal Disease: Recommended vaccinations
| General recommendation | |
| Recommendation for specific groups only | |
| Catch-up (e.g. if previous doses missed) | |
| Vaccination not funded by the National Health system | |
| Mandatory vaccination |
| Months | Years | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 3 | 4 | 5 | 6 | 11 | 12 | 13 | 14 | 15 | 2 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 24 | ≥ 25 | ||
| Austria | MenB1 | MenB1 | MCV4/MenB | MCV4 | ||||||||||||||||||||
| Belgium | MCV4 | MCV4 | ||||||||||||||||||||||
| Bulgaria | ||||||||||||||||||||||||
| Croatia | ||||||||||||||||||||||||
| Cyprus | MCV4 | MPSV42 | ||||||||||||||||||||||
| Czechia | MenB3 | MenB4 | MCV4/MenB5 | MCV4/MenB6 | ||||||||||||||||||||
| Denmark | ||||||||||||||||||||||||
| Estonia | ||||||||||||||||||||||||
| Finland | ||||||||||||||||||||||||
| France | MenB7 | MenB | MCV48 | MCV4/MenB | MenC9 | |||||||||||||||||||
| Germany | MenB | MenB | MenB - MenC10 | MenC | ||||||||||||||||||||
| Greece | MCV4/MenB | MenC | MenC | MCV4 | MCV4 | MCV4/MenB | ||||||||||||||||||
| Hungary | MenC | MenC | MenC11 | |||||||||||||||||||||
| Iceland | MCV4 | |||||||||||||||||||||||
| Ireland | MenB | MenB | MenC | MenB | MenC12 | MCV4 | ||||||||||||||||||
| Italy | MenB13 | MenB13 | MCV4 | MenB13 | MenB13 | MCV414 | ||||||||||||||||||
| Latvia | ||||||||||||||||||||||||
| Liechtenstein | MCV415 | MCV416 | ||||||||||||||||||||||
| Lithuania | MenB | MenB | MenB17 | |||||||||||||||||||||
| Luxembourg | MenB | MenB | MenB | MCV4 | MCV4 | |||||||||||||||||||
| Malta | MenB | MCV4 | MenB | MenB | MCV4 | MCV4 | ||||||||||||||||||
| Netherlands | MCV418 | MCV418 | ||||||||||||||||||||||
| Norway | ||||||||||||||||||||||||
| Poland | MenC | MenC | ||||||||||||||||||||||
| Portugal | MenB | MenB | MenB - MenC | |||||||||||||||||||||
| Romania | ||||||||||||||||||||||||
| Slovakia | MenB | MenB | MCV4/MenB | MCV4/MenB19 | ||||||||||||||||||||
| Slovenia | ||||||||||||||||||||||||
| Spain | MenB20 | MenB - MenC20 | MenB - MenC20 | MCV421 | MCV422 | |||||||||||||||||||
| Sweden | ||||||||||||||||||||||||
Footnotes:
- Please refer to official recommendations for timing and number of doses required according to age. For infants, 3 doses from 3 months of age with at least one month interval - Booster between 13-15 months.
- vaccines only given on specific indications
- 1.Vaccination with MenB vaccine is covered by health insurance for persons of all ages with immune disorders since January 2018. 2. Vaccination for small infants with MenB is covered by health insurance since May 2020 if the schedule is started before the age of 1 year. 3. Vaccination for adolescents with MenB vaccine is covered by health insurance since January 2022 if vaccination is started at the age interval from 14 to 16 years. More details of the recommendation is available at: https://szu.cz/wp-content/uploads/2024/01/2024-Recommendation-for-vaccination-against-IMD.pdf
- 1.Vaccination with MenB vaccine is covered by health insurance for persons of all ages with immune disorders since January 2018. 2. Vaccination for small infants with MenB is covered by health insurance since May 2020 if the schedule is started before the age of 1 year. 3. Vaccination for adolescents with MenB vaccine is covered by health insurance since January 2022 if vaccination is started at the age interval from 14 to 16 years. More details of the recommendation is available at: https://szu.cz/wp-content/uploads/2024/01/2024-Recommendation-for-vaccination-against-IMD.pdf
- MenB 1.Vaccination with MenB vaccine is covered by health insurance for persons of all ages with immune disorders since January 2018. 2. Vaccination for small infants with MenB is covered by health insurance since May 2020 if the schedule is started before the age of 1 year. 3. Vaccination for adolescents with MenB vaccine is covered by health insurance since January 2022 if vaccination is started at the age interval from 14 to 16 years. MCV4 1.Vaccination with MCV4 vaccine is covered by health insurance for persons of all ages with immune disorders since January 2018. 2. Vaccination for toodlers with MCV4 vaccine is covered by health insurance since May 2020 if is administered at the age interval from 12 to 23 months. 3.Vaccination for adolescents with MCV4 vaccine is covered by health insurance since January 2022 if is administered at the age interval from 14 to 16 years. More details of the recommendation is available at: https://szu.cz/wp-content/uploads/2024/01/2024-Recommendation-for-vaccination-against-IMD.pdf
- MenB 1.Vaccination with MenB vaccine is covered by health insurance for persons of all ages with immune disorders since January 2018. 2. Vaccination for small infants with MenB is covered by health insurance since May 2020 if the schedule is started before the age of 1 year. 3. Vaccination for adolescents with MenB vaccine is covered by health insurance since January 2022 if vaccination is started at the age interval from 14 to 16 years. MCV4 1.Vaccination with MCV4 vaccine is covered by health insurance for persons of all ages with immune disorders since January 2018. 2. Vaccination for toodlers with MCV4 vaccine is covered by health insurance since May 2020 if is administered at the age interval from 12 to 23 months. 3.Vaccination for adolescents with MCV4 vaccine is covered by health insurance since January 2022 if is administered at the age interval from 14 to 16 years. More details of the recommendation is available at: https://szu.cz/wp-content/uploads/2024/01/2024-Recommendation-for-vaccination-against-IMD.pdf
- Vaccination introduced in 2022. Mandatory since January 2025.
- Introduced in January 2025 in replacement of monovalent MenC
- 1 dose until 24 years
- Introduction of MenB vaccine in January 2025
- Since January 1st, 2017, the meningococcal C vaccine is offered to all children aged under 2 years with 100% reimbursement on a voluntary-based approach.
- Hib/MenC combined vaccine
- Please refer to local recommendations for age of administration. MenB should not to be co-administered with other vaccinations.
- Meningococcal ACWY, one dose for adolescents age 12-18
- Not part of the routine vaccination programme but can be offered by health professionals. Catch-up possible until 5 years of age.
- Not part of the routine vaccination programme but can be offered by health professionals. Catch-up possible until 20 years of age.
- Can be administered concomitantly with MMR
- More information available at https://rijksvaccinatieprogramma.nl/vaccinaties/menacwy
- One dose of each vaccine if given between 14 and 15 years
- Additional information available at https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/comoTrabajamos/enf-meningococica.htm
- One dose at 12 years to individuals who have not received any doses of MCV4 since 10 years of age. Additional information available at https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/comoTrabajamos/enf-meningococica.htm
- The catch-up vaccination programme for individuals aged 13 to 18 years will be introduced gradually (more information available at: https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/programasDeVacunacion/adolescentes-meningo/home.htm